The 3rd Exosome-Based Therapeutic Development Summit returns with a more comprehensive agenda than ever before, reuniting leading pharma, biotech, technology providers and academic teams to advance therapeutically relevant exosome-based therapeutics in regenerative medicine, autoimmunity, COVID-19 and beyond.
Tailor-made to showcase the latest innovations and interactively discuss the industry’s most important talking points, join leading biopharmaceutical Directors, VPs and C-Level Executives to successfully optimize, accelerate and scale your exosome-based therapeutics as next generation drugs for unmet clinical needs
Key Highlights:
- Shining a spotlight on orally delivered bacterial extracellular vesicles with unique pharmacological profiles with striking anti-inflammatory effects, an exciting new approach for exosome therapeutics with Evelo Biosciences
- Deep dive into the latest data coming out of the clinic with key learnings from phase I/II trials of Covid-19, oesteoarthirtus and gastrointestinal diseases with insights from Organicell, University of Athens & University of Louisville
- Navigating the complex regulatory landscape for exosomes to understand what the FDA requires to progress through each development stage and the potential for successful applications into 2021 with insights from Rion
- Exploring proteomic insights in understanding EVs and the mechanisms of action of EV-mediated RNA delivery to enable more efficient and efficacious exosome therapies with Exogenus Therapeutics Aruna Bio, Stem XO & Baker Heart and Diabetes Institute
- Expanding the boundaries of engineering exosomes including cell selection, applications of the technology, monitoring biodistribution and enabling direct delivery with Exogenus VivaZome Therapeutics, OmniSpriant & Exogenus Therapeutics
To know more visit: https://ter.li/h99vsb